Missoula, MT, December 28, 2023 – Inimmune, a leading clinical stage biotech company focused on the
development of novel vaccines and immunotherapies announced today that its Chief Scientific and Strategy Officer, Jay Evans, Ph.D., will give a company presentation at World Vaccine Congress (West Coast).
Innovative vaccine adjuvants and delivery technologies have demonstrated great progress for treatment and prevention of respiratory infections. Inimmune Corporation has an advanced portfolio of vaccine technologies and immunotherapy treatements focused in areas of high unmet need and global health prorities.
“Inimmune has a remarkable pipeline of clinical stage vaccine adjuvants and is poised to change the landscape of technologies available for the prevention or treatment of respiratory diseases,” said Alan Joslyn, CEO of
Inimmune. “We are excited to have Dr. Evans represent Inimmune at World Vaccine Congress and provide an update on the innovative vaccine research being conducted at Inimmune.”
The World Vaccine Congress will be held November 27-30 at the Santa Clara Convention Center (Santa Clara,
California). The Congress will bring together industry experts in the areas of infectious disease vaccines,
antiviral treatments, and cancer immunotherapy to showcase next-generation technologies.
About Inimmune Corporation
Inimmune Corp. (Missoula, MT) is a privately held biotechnology company focused on the discovery and development of innovative immunotherapeutics, vaccine adjuvants, and vaccines. Inimmune is harnessing the human immune system to create safe and effective treatments for allergy, infectious disease, autoimmunity, and cancer. Their laboratories and offices are housed in the Montana Technology Enterprise Center (MonTEC) in Missoula.
For more information on Inimmune’s research and development of novel vaccine adjuvants and delivery systems, please visit www.inimmune.com.